Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7021-7030 Newer>

The Motley Fool December 27, 2010 Brian Orelli	Painful Clinical Hold? Not Really. Regeneron offers the benefits of a full pipeline.
The Motley Fool December 27, 2010 Brian D. Pacampara	BioSante Pharmaceuticals Shares Popped: What You Need to Know Shares of BioSante Pharmaceuticals, which develops products for female sexual health and oncology, soared a staggering 28% in intraday trading on extraordinarily high volume.
The Motley Fool December 27, 2010 Brian Orelli	FDA Kicks Dust on Alimera's Fairy Tale Eight months after its IPO, Alimera gets hammered.
The Motley Fool December 27, 2010 Seth Jayson	Why Zimmer Holdings' Earnings Are Outstanding With 10.1% of operating cash flow coming from questionable sources, Zimmer Holdings investors should take a closer look at the underlying numbers.
The Motley Fool December 23, 2010 Brian Orelli	Corcept May Have Hit Pay Dirt Corcept's Corlux tackles Cushing's syndrome.
The Motley Fool December 23, 2010 Seth Jayson	Why Wall Street Should Love Teleflex's Earnings Teleflex's issue isn't questionable cash flow boosts, but rather items in that suspect group that actually reduced cash flow.
The Motley Fool December 23, 2010 Seth Jayson	Why Wall Street Should Love Medtronic's Earnings Over the past 12 months, Medtronic turned 24.7% of its revenue into free cash flow.
The Motley Fool December 22, 2010 Brian Orelli	Arena Charges On It seems Fool readers were a little more optimistic about the timing of Arena Pharmaceuticals' resubmission of its obesity drug to the Food and Drug Administration than the company is.
Chemistry World December 22, 2010 Sarah Houlton	Fines, Flu and an Uncertain Future It was another tough year for the pharma industry, with downsizing, pricing concerns and the impending expiration of patents on many products. But some of the biggest headlines were caused by eye-watering fines dished out in the US.
The Motley Fool December 22, 2010 Matt Koppenheffer	Arena Pharmaceuticals Shares Plunged: What You Need to Know Shares of biopharma company Arena Pharmaceuticals dipped as much as 13% in intraday trading on massive volume.
<Older 7021-7030 Newer> Return to current articles.